Both of these players are leaders in their fields.

X4 Pharmaceuticals is a BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending ...

Innovative Pharmaceutical Biotech (HK:0399) has released an update. Innovative Pharmaceutical Biotech Limited has entered into a Memorandum of Understanding to potentially acquire a majority stake in ...

From billion-dollar licensing deals to advances in cancer therapies and artificial intelligence, Chinese biotech firms are ...

F rom blockbuster drugs that garner media attention to smaller innovations that help millions maintain health, the biotech and pharmaceutical industries have an impact on everyone’s life. Meanwhile, ...

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied about 35% over the past six months (as of Nov. 20, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 12%). Year to ...

In September 2024, Akeso, a little-known Chinese biopharmaceutical company, announced that clinical trials had shown that its new drug could halt the progression of a type of lung cancer for nearly a ...

DUBLIN--(BUSINESS WIRE)--The "Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2020-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive ...

Two companies are partnering with each other to create sustainable proteins that don't require animals, potentially transforming the future of sustainable food production. The joint venture is ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

MONTREAL, Feb. 18, 2026 /CNW/ - E-Biotech® today formally announced the launch of its patent-pending artificial intelligence infrastructure platform for pharmaceutical and GMP compliance, following ...

This player's pipeline should keep growth going over the long run.